WO2025003977 - IN VITRO TRANSCRIPTION METHOD
National phase entry is expected:
Publication Number
WO/2025/003977
Publication Date
02.01.2025
International Application No.
PCT/IB2024/056309
International Filing Date
28.06.2024
Title **
[English]
IN VITRO TRANSCRIPTION METHOD
[French]
PROCÉDÉ DE TRANSCRIPTION IN VITRO
Applicants **
SEQIRUS INC.
475 Green Oaks Parkway
Holly Springs, North Carolina 27540, US
Inventors
CHANG, Cheng
c/ Seqirus Inc.
475 Green Oaks Parkway
Holly Springs, North Carolina 27540, US
Priority Data
63/510,969
29.06.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1561 | |
| EPO | Filing, Examination | 11107 | |
| Japan | Filing | 595 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 8880 |
Total: 22717 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure relates generally to methods of producing RNA from a DNA template. More particularly, the method of the present disclosure comprises an in vitro transcription method for producing RNA from close-ended DNA (ceDNA) templates.[French]
La présente divulgation concerne de manière générale des procédés de production d'ARN à partir d'une matrice d'ADN. Plus particulièrement, le procédé de la présente divulgation comprend un procédé de transcription in vitro pour produire de l'ARN à partir de matrices d'ADN à extrémité fermée (ADNce).